A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)

Brief description of study

The purpose of this research study is to test whether the combination of the study drugs pembrolizumab and mRNA-4157 works better than just pembrolizumab to prevent your type of cancer from coming back. This study will also look at safety and tolerability, and whether mRNA 4157 and pembrolizumab have any effect on your immune system; samples of your blood will be taken to examine immune markers. In this study, some patients on this study will take just pembrolizumab, and some patients will take the combination of both pembrolizumab and mRNA-4157.


Clinical Study Identifier: s18-01981
ClinicalTrials.gov Identifier: NCT03897881
Principal Investigator: Jeffrey S. Weber.
Other Investigators: Nila Theresa De La Rosa, Maya Dimitrova, Kristen Spencer, Kathleen M Madden, Rafael Winograd, Janice Mehnert.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.